260 related articles for article (PubMed ID: 23924493)
1. HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection.
Akbar SM; Al-Mahtab M; Uddin MH; Khan MS
Hepatobiliary Pancreat Dis Int; 2013 Aug; 12(4):363-9. PubMed ID: 23924493
[TBL] [Abstract][Full Text] [Related]
2. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
4. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B.
Le Bert N; Salimzadeh L; Gill US; Dutertre CA; Facchetti F; Tan A; Hung M; Novikov N; Lampertico P; Fletcher SP; Kennedy PTF; Bertoletti A
J Hepatol; 2020 Jan; 72(1):34-44. PubMed ID: 31348999
[TBL] [Abstract][Full Text] [Related]
5. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
[TBL] [Abstract][Full Text] [Related]
6. [The characteristic of T cells response to HBV-specific antigen proteins in patients with HBV infection].
Feng X; Yan HP; Liao HY; Liu YM; Zhang GY; Lin F; Zhao Y; Huang YL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Aug; 26(4):253-5. PubMed ID: 23189836
[TBL] [Abstract][Full Text] [Related]
7. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
8. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
Zhang TY; Guo XR; Wu YT; Kang XZ; Zheng QB; Qi RY; Chen BB; Lan Y; Wei M; Wang SJ; Xiong HL; Cao JL; Zhang BH; Qiao XY; Huang XF; Wang YB; Fang MJ; Zhang YL; Cheng T; Chen YX; Zhao QJ; Li SW; Ge SX; Chen PJ; Zhang J; Yuan Q; Xia NS
Gut; 2020 Feb; 69(2):343-354. PubMed ID: 30926653
[TBL] [Abstract][Full Text] [Related]
9. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
[TBL] [Abstract][Full Text] [Related]
10. Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients.
Yim SY; Kim TH; Jun SS; Kim ES; Keum B; Seo YS; Yim HJ; Jeen YT; Chun HJ; Lee HS; Um SH; Kim CD; Won NH; Ryu HS
Gut Liver; 2017 May; 11(3):417-425. PubMed ID: 28208002
[TBL] [Abstract][Full Text] [Related]
11. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection.
Akbar SM; Yoshida O; Chen S; Cesar AJ; Abe M; Matsuura B; Hiasa Y; Onji M
Antivir Ther; 2010; 15(6):887-95. PubMed ID: 20834101
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).
Al Mahtab M; Akbar SMF; Aguilar JC; Guillen G; Penton E; Tuero A; Yoshida O; Hiasa Y; Onji M
PLoS One; 2018; 13(8):e0201236. PubMed ID: 30133478
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV.
Vanwolleghem T; Groothuismink ZMA; Kreefft K; Hung M; Novikov N; Boonstra A
J Hepatol; 2020 Jul; 73(1):52-61. PubMed ID: 32061650
[TBL] [Abstract][Full Text] [Related]
14. Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
Huang D; Sansas B; Jiang JH; Gong QM; Jin GD; Calais V; Yu DM; Zhu MY; Wei D; Zhang DH; Inchauspé G; Zhang XX; Zhu R
J Viral Hepat; 2017 Nov; 24 Suppl 1():66-74. PubMed ID: 29082648
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B.
Al-Mahtab M; Akbar SM; Aguilar JC; Uddin MH; Khan MS; Rahman S
Hepatol Int; 2013 Oct; 7(4):981-9. PubMed ID: 26202028
[TBL] [Abstract][Full Text] [Related]
16. Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides.
Akbar SM; Al-Mahtab M; Khan MS
Expert Opin Biol Ther; 2013 Jul; 13(7):1063-74. PubMed ID: 23581572
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of HBsAg and HBcAg in hepatocytes in chronic hepatitis B].
Wang GS; Wang MM; Xie QL; Ming L; Jiang XN; Chen LW; Liu MH
Zhonghua Gan Zang Bing Za Zhi; 2004 May; 12(5):287-9. PubMed ID: 15161505
[TBL] [Abstract][Full Text] [Related]
18. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
Chen X; Li M; Le X; Ma W; Zhou B
Vaccine; 2004 Jan; 22(3-4):439-46. PubMed ID: 14670326
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of antiviral - passive - active immunization ("sandwich") therapeutic strategy for functional cure of chronic hepatitis B in mice.
Shi B; Wu Y; Wang C; Li X; Yu F; Wang B; Yang Z; Li J; Liang M; Wen Y; Ying T; Yuan Z
EBioMedicine; 2019 Nov; 49():247-257. PubMed ID: 31680000
[TBL] [Abstract][Full Text] [Related]
20. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
